Reportlinker Adds Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018
NEW YORK, May 31, 2011 — /PRNewswire/ — Reportlinker.com announces that a new commercialise inquiry account is useable in its catalog:
Global Marketplace for Hormonal Contraceptives and Sterility Drugs, 2011-2018
http://www.reportlinker.com/p0512284/Global-Market-for-Hormonal-Contraceptives-and-Infertility-Drugs-2011-2018.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Provides psychoanalysis of terminated ten key marketed products and indentifies terminated 40 R&D candidates in presymptomatic to clinical stages of evolution.
Future Therapies for Nativity Ascendancy and Generative Wellness
The flow mart for hormonal contraceptives and sterility drugs is estimated at US$9.4bn, and is prognosis to gain by 7% in yearbook revenues to US$10bn by 2014.
In this theme, The Planetary Commercialize for Hormonal Contraceptives and Sterility Drugs, 2011-2018 - Future Therapies for Birthing Controller and Generative Wellness (2nd Edition) the referee testament be introduced to an psychoanalysis of stream production markets, explore and developing themes, and accompany activities inside the battlefield.
The theme provides insights for intersection annex and reformulation, sales forecasts to 2018, and allows for assessments of the hob of late-stage grapevine drugs on the mart. An overview of R&D programs inside the study is too presented screening products from presymptomatic to premarket potency phases of growing. Therapy region prognostication to 2018 enables the proofreader to brand key assumptions around hereafter markets and prospects, and utilise the information for proprietorship prognostic mart model.
-The universal grocery for hormonal contraceptives is estimated at US$6.9bn in 2011, but is expected to step-down roughly 19.5% in one-year revenues to US$5.5bn by 2018.
-Drivers of emergence for the hormonal contraception sphere bequeath be refreshing percutaneous and intravaginal products that pass greater efficaciousness, frown dosing, and improved and yearner ascendance terminated menstruum.
-Currently, thither are complete 40 grapevine candidates for distaff and manly contraception.
-The stream world-wide marketplace for sterility drugs is US$2.5bn; still the sterility therapy sphere is underserved with drugs that are chiefly focussed on distaff sterility that make ovulation for aided excogitation programs.
-Mart leadership in the sterility sphere admit Merck Serono, Merck & Co., and Ferring with estimated revenues for their sterility products in 2011 at US$955m, US$625m and US$550m, severally.
-Drivers of outgrowth testament be done institution to: concentrate face effects associated with pituitary-gonadal drugs; heighten qualitative and quantitative aspects of ovulation and spermatogenesis; and amend boilersuit fertilisation and pregnancy-birth rates.
-The virile and distaff sterility R&D arena is ailing served with solitary 15 grapevine candidates identified as potency clinical candidates.
Questions answered by this story admit:
-Which contraceptives and sterility drugs are the stream and voltage succeeding commercialise leadership
-What elf new dose approvals testament bear on the procreative medication dose commercialize
-Which premarket drugs are identified as high-value products
-Which companies are underdeveloped hormonal contraceptives and sterility drugs
-Sales predictions to 2018 for prima contraceptives and sterility drugs
-How volition newcomers impact the merchandise emplacement of mart leadership
-What are recession commercialise opportunities in generative medicament
-What the succeeding lookout holds for hormonal contraceptives and sterility pharmacotherapies
-How companies are expanding the worldwide generative medicate grocery done advanced reformulations and junior-grade indications for endocrinological and gynecologic disorders
-Which molecules and compounds are master R&D clusters in generative medicament
The contents of this URCH Publication theme are derived from in-depth research-based surveys of the manufacture and proprietorship analytic judgment tools. Beginning fabric too comprises the followers:
Market information abstract - contraception and sterility
1.2 Marketplace Psychoanalysis for Contraception and Sterility
2.4.1.3 Sales Estimates and Production Commercialize Mentality
2.4.2.2 Sales Forecasts and Merchandise Grocery Mindset
2.4.3.2 Sales Estimates and Intersection Commercialise Mindset
2.4.4.2 Sales Estimates and Intersection Commercialize Prospect
2.4.5.3 Sales Estimates and Production Marketplace Mind-set
2.5 Succeeding Considerations and Mentality for the Preventative Production Mart
Mechanism of Fulfil of Sterility Pharmacotherapeutics
3.3.1.2 Sales Estimates and Production Grocery Mindset
3.3.2.2. Sales Estimates and Intersection Mart Expectation
3.3.4.2 Sales Estimates and Intersection Mart Mind-set
3.4 Mart Expectation for Sterility Pharmacotherapeutics
4. Explore and Growth in Generative Wellness
4.3 Contraception - Inquiry and Developing Overview
6.3.2.1 Sterility - Inquiry and Growth Overview
Postpone 1.1 Estimated World-wide Sales (US$m) & Forecasts of Prima Hormonal Contraceptives and Sterility Drugs, 2011-2018
Board 2.1 Pick of Hormonal Contraceptives Segmental by Expression and Deliverance Path, 2011
Tabularise 2.2 Bayer’s Hormonal Preventive Production Portfolio, 2011
Mesa 2.3 Bayer`s Grapevine Prophylactic Candidates, 2011
Mesa 2.4 Estimated Sales (US$) and Yearly Maturation (%) of Bayer’s Stellar Hormonal Antifertility Products, 2011-2018
Board 2.5 Johnson & Johnson`s Hormonal Preventive Ware Portfolio, 2011
Tabularize 2.6 Estimated Sales (US$m) and One-year Ontogeny (%) of Johnson & Johnson`s Starring Hormonal Preventative Products, 2011-2018
Mesa 2.7 Merck & Co’s Hormonal Preventive Merchandise Portfolio, 2011
Tabulate 2.8 Estimated Sales (US$m) and Yearly Ontogeny (%) of Merck & Co’s Starring Hormonal Prophylactic Products, 2011-2018
Tabularise 2.9 Pfizer`s Hormonal Preventive Intersection Portfolio, 2011
Board 2.10 Estimated Sales (US$m) and Yearly Development (%) of Pfizer`s Stellar Hormonal Prophylactic Products, 2011-2018
Mesa 2.11 Teva`s Hormonal Antifertility Merchandise Portfolio, 2011
Tabulate 2.11 Teva`s Hormonal Preventative Intersection Portfolio, 2011 (continued)
Tabularise 2.12 Estimated Sales (US$m) and Yearly Outgrowth (%) of Teva`s Stellar Hormonal
Defer 3.2 Ferring`s Sterility Production Portfolio, 2011
Tabularize 3.3 Estimated World Sales (US$m) and One-year Ontogenesis (%) of Ferring`s Sterility Products, 2011-2018
Tabulate 3.4 Merck & Co.`s Hormonal Sterility Merchandise Portfolio, 2011
Tabularise 3.5 Estimated World-wide Sales (US$m) and Yearly Maturation (%) of Merck & Co.’s Hormonal Sterility Products, 2011-2018
Defer 3.6 Merck Serono`s Hormonal Sterility Production Portfolio, 2011
Tabularize 3.7 Estimated World Sales (US$m) and One-year Emergence (%) of Merck Serono`s Hormonal Sterility Products, 2011-2018
Tabularize 4.1 Distaff Viva Contraceptives in Maturation, 2011
Tabulate 4.1 Distaff Unwritten Contraceptives in Growing, 2011 (continued)
Tabularise 4.2 Percutaneous/Transmucosal Distaff Contraceptives in Growth, 2011
Mesa 4.3 Implantable/Injectable Distaff Contraceptives in Ontogenesis, 2011
Postpone 4.4 Manlike Contraceptives in Developing, 2011
Tabularise 4.5 Drugs in Growth for Distaff Sterility, 2011
Board 4.6 Drugs in Growth for Manlike Sterility, 2011
Design 1.1 Estimated Sales (US$m) and Forecasts of Prima Hormonal Contraceptives and Sterility Drugs, 2011-2018
Pattern 1.2 Estimated Ball-shaped Commercialize Portion for Hormonal Contraceptives and Sterility Dose Sectors, 2011 & 2018
Design 2.1 World Receipts Trends for Bayer’s Star Hormonal Antifertility Products, 2005-2010
Bod 2.2 Ball-shaped Gross Trends for Johnson & Johnson’s Stellar Hormonal Preventive Products, 2005-2010
Design 2.3 Globose Taxation Trends for Merck & Co’s Prima Hormonal Preventative Products, 2005-2010
Anatomy 2.4 Planetary Merchandise Sales for Pfizer’s Hormonal Antifertility Dealership, 2005-2010
Pattern 2.5 World Sales Trends of Teva’s Stellar Hormonal Antifertility Products, 2005-2010
Bod 2.6 Preeminent Hormonal Preventive Products by Sales Receipts (US$m), 2011 (estimated)
Number 3.1 World Sales Trends of Merck & Co.’s Prima Hormonal Sterility Products, 2005-2010
Number 3.2 Ball-shaped Sales Trends of Merck Serono’s Leadership Hormonal Sterility Products,
Pattern 3.3 Starring Hormonal Sterility Products by Sales Gross (US$m), 2011 (estimated)
To ordering this composition:
Drug and Medicine Industriousness : Global Mart for Hormonal Contraceptives and Sterility Drugs, 2011-2018
Check our Caller Visibility, DRUM and Taxation Psychoanalysis!
Reader comments on Sacbee.com are the opinions of the author, not The Sacramento Bee. If you see an exceptionable commentary, penetrate the droop ikon downstairs it. We testament edit comments containing incompatible links, obscenities, detest address, and personal attacks. Gross or echo violators leave be prohibited. See more some comments hither.
Sacbee.com is glad to offer a assembly for lector interaction, give-and-take, feedback and response to our stories. Still, we second-stringer the rightfield to edit unfitting comments or ban users who can’t gambol prissy. ( See our entire damage of avail hither. )
Here are roughly rules of the route:
? Sustenance your comments polite. Don’t contumely one another or the subjects of our articles. If you remember a gloss violates our guidelines dog the pin ikon to advise the moderators. Responding to the gloss leave but promote bad demeanor.
? Don’t use profanities, vulgarities or detest address. This is a ecumenical pursuit intelligence place. Sometimes, thither are children deliver. Don’t say anything in a way yo…
